通过整合数据挖掘技术发现用于产前唐氏综合征筛查的新型血清生物标志物。
Discovery of novel serum biomarkers for prenatal Down syndrome screening by integrative data mining.
机构信息
Laboratory for Health Protection Research (GBO), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
出版信息
PLoS One. 2009 Nov 24;4(11):e8010. doi: 10.1371/journal.pone.0008010.
BACKGROUND
To facilitate the experimental search for novel maternal serum biomarkers in prenatal Down Syndrome screening, we aimed to create a set of candidate biomarkers using a data mining approach.
METHODOLOGY/PRINCIPAL FINDINGS: Because current screening markers are derived from either fetal liver or placental trophoblasts, we reasoned that new biomarkers can primarily be found to be derived from these two tissues. By applying a three-stage filtering strategy on publicly available data from different sources, we identified 49 potential blood-detectable protein biomarkers. Our set contains three biomarkers that are currently widely used in either first- or second-trimester screening (AFP, PAPP-A and fbeta-hCG), as well as ten other proteins that are or have been examined as prenatal serum markers. This supports the effectiveness of our strategy and indicates the set contains other markers potentially applicable for screening.
CONCLUSIONS/SIGNIFICANCE: We anticipate the set will help support further experimental studies for the identification of new Down Syndrome screening markers in maternal blood.
背景
为了促进产前唐氏综合征筛查中新型母体血清生物标志物的实验研究，我们旨在使用数据挖掘方法创建一组候选生物标志物。
方法/主要发现：由于当前的筛查标志物源自胎儿肝脏或胎盘滋养层细胞，我们推断新的标志物主要可以从这两种组织中找到。通过对来自不同来源的公开可用数据应用三阶段过滤策略，我们鉴定出 49 种潜在的血液可检测蛋白生物标志物。我们的集合包含三种目前广泛用于第一或第二孕期筛查的标志物（AFP、PAPP-A 和 fβ-hCG），以及另外十种作为产前血清标志物进行过或正在研究的蛋白质。这支持了我们策略的有效性，并表明该集合包含其他可能适用于筛查的标志物。
结论/意义：我们预计该集合将有助于支持进一步的实验研究，以确定母体血液中的新型唐氏综合征筛查标志物。
Zotero 插件